Sagar Anil Patel

Sagar Anil Patel

Auto-generated profile, based on publicly available information

Sagar Anil Patel

Department of Radiation Oncology, Emory University, Atlanta, Georgia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
SPSagar A. Patel
Sagar A. Patel
MQMuhammad M. Qureshi
Muhammad M. Qureshi
MDMichael A. Dyer
Michael A. Dyer
SJScharukh Jalisi
Scharukh Jalisi
GGGregory Grillone
Gregory Grillone
MTMinh Tam Truong
Minh Tam Truong

1 February 2022 in Clinical Breast Cancer
Verified
Journal Article
Closed access
ASAshley Schlafstein
Ashley Schlafstein
YLYuan Liu
Yuan Liu
SGSubir Goyal
Subir Goyal
SKShannon Kahn
Shannon Kahn
KGKaren Godette
Karen Godette
SPSagar A. Patel
Sagar A. Patel

29 March 2017 in Head & Neck
Verified
Journal Article
Closed access
PDF file
SPSagar A. Patel
Sagar A. Patel
MQMuhammad M. Qureshi
Muhammad M. Qureshi
KMKimberley S. Mak
Kimberley S. Mak
DSDebjani Sahni
Debjani Sahni
NGNicholas J. Giacalone
Nicholas J. Giacalone
MTMinh Tam Truong
Minh Tam Truong

28 August 2020 in Clinical Genitourinary Cancer
Verified
Journal Article
Open access
YLYuan Liu
Yuan Liu
SPSagar A. Patel
Sagar A. Patel
AJAshesh B. Jani
Ashesh B. Jani
TGTheresa W. Gillespie
Theresa W. Gillespie
PPPretesh R. Patel
Pretesh R. Patel
MMMark W. McDonald
Mark W. McDonald
There are few comparative outcomes data regarding the therapeutic delivery of proton beam therapy (PBT) versus the more widely used photon-based external-beam radiation (EBRT) and brachytherapy (BT). We evaluated the impact of PBT on overall survival (OS) compared to EBRT or BT on patients with localized prostate cancer. The National Cancer Data Base (NCDB) was queried for 2004–2015. Men with clinical stage T1–3, N0, M0 prostate cancer treated with radiation, without surgery or chemotherapy, were included. OS, the primary clinical outcome, was fit by Cox proportional hazard model. Propensity score matching was implemented for covariate balance. There were 276,880 eligible patients with a median follow-up of 80.9 months. A total of 4900 (1.8%) received PBT, while 158,111 (57.1%) received EBRT and 113,869 (41.1%) BT. Compared to EBRT and BT, PBT patients were younger and were less likely to be in the high-risk group. On multivariable analysis, compared to PBT, men had worse OS after EBRT (adjusted hazard ratio [HR] = 1.72; 95% confidence interval [CI], 1.51–1.96) or BT (adjusted HR = 1.38; 95% CI, 1.21–1.58). After propensity score matching, the OS benefit of PBT remained significant compared to EBRT (HR = 1.64; 95% CI, 1.32–2.04) but not BT (adjusted HR = 1.18; 95% CI, 0.93–1.48). The improvement in OS with PBT was most prominent in men ≤ 65 years old with low-risk disease compared to other subgroups (interaction P < .001). In this national data set, PBT was associated with a significant OS benefit compared to EBRT, and with outcomes similar to BT. These results remain to be validated by ongoing prospective trials.

23 July 2025 in Brachytherapy
Verified
Journal Article
Closed access
SPSagar A. Patel
Sagar A. Patel
MKMarisa Kollmeier
Marisa Kollmeier
JCJuanita Crook
Juanita Crook
DKDaniel Krauss
Daniel Krauss
GMGerard Morton
Gerard Morton
MKMitchell R. Kamrava
Mitchell R. Kamrava

3 August 2023 in Cancer Medicine
Verified
Journal Article
Open access
JJJames Janopaul-Naylor
James Janopaul-Naylor
TCTaylor J. Corriher
Taylor J. Corriher
JSJeffrey Switchenko
Jeffrey Switchenko
SHSheela Hanasoge
Sheela Hanasoge
AEAshanda Esdaille
Ashanda Esdaille
SPSagar A. Patel
Sagar A. Patel
Background: Delayed access to care may contribute to disparities in prostate cancer (PCa). The Affordable Care Act (ACA) aimed at increasing access and reducing healthcare disparities, but its impact on timely treatment initiation for PCa men is unknown.Methods: Men with intermediate‐ and high‐risk PCa diagnosed 2010–2016 and treated with curative surgery or radiotherapy were identified in the National Cancer Database. Multivariable logistic regression modeled the effect of race and insurance type on treatment delay >180 days after diagnosis. Cochran–Armitage test measured annual trends in delays, and joinpoint regression assessed if 2014, the year the ACA became fully operationalized, was significant for inflection in crude rates of major delays.Results: Of 422,506 eligible men, 18,720 (4.4%) experienced >180‐day delay in treatment initiation. Compared to White patients, Black (OR 1.79, 95% CI 1.72–1.87, p < 0.001) and Hispanic (OR 1.37, 95% CI 1.28–1.48, p < 0.001) patients had higher odds of delay. Compared to uninsured, those with Medicaid had no difference in odds of delay (OR 0.94, 95% CI 0.84–1.06, p = 0.31), while those with private insurance (OR 0.57, 95% CI 0.52–0.63, p < 0.001) or Medicare (OR 0.64, 95% CI 0.58–0.70, p < 0.001) had lower odds of delay. Mean time to treatment significantly increased from 2010 to 2016 across all racial/ethnic groups (trend p < 0.001); 2014 was associated with a significant inflection for increase in rates of major delays.Conclusions: Non‐White and Medicaid‐insured men with localized PCa are at risk of treatment delays in the United States. Treatment delays have been consistently rising, particularly after implementation of the ACA.